Aptar Pharma Twister Chosen for Asthma Therapy
![](/46/pdcnewsitem/03/43/44/kbC2vB1BhCMoEDW.jpg)
Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new Budesonide Dry Powder Inhaler (DPI), which uses Aptar Pharma’s novel, user-friendly and cost-effective Twister DPI.
The first drug product marketed with Twister Budesonide DPI is designed for maintenance therapy in the treatment of asthma. Budesonide DPI is one of the first drug products manufactured locally and marketed in China. This cost-effective drug product incorporates Aptar Pharma’s Twister technology. Budesonide DPI contains an inhaled corticosteroid for the treatment of asthma in adults and children age six and over. The product is marketed in two versions, one version containing 30 capsules and the other, 60 capsules.
Each capsule consists of 200µg of budesonide blended with lactose monohydrate as the carrier.
Key benefits of Aptar Pharma’s Twister
Twister is a new capsule-based DPI, designed and developed by a multidisciplinary technical team based at Aptar Pharma’s Centre of Excellence in Le Vaudreuil, France to specifically address unmet medical needs in fast-growing markets.
Twister has a simple and robust design with few components, making it costeffective for asthma and COPD treatments, and has been tested and validated with a number of different dry powder drug formulations.
Twister is designed to be patient-friendly and easy to use, allowing patients easy access to their medication in three simple steps: insert, twist and inhale. To help improve patient compliance with the prescribed treatment, Twister is transparent, allowing the capsule and powder to be seen in the device as they are administered. In addition to these visual cues, the patient is also guided by audible feedback during inhalation.
“Shanghai Sine Promod Pharmaceutical is one of Aptar Pharma’s key customers in China. We are particularly proud to have supported their Budesonide DPI program through the development and commercialization of Twister, manufactured locally in our Suzhou facility. This is a very important milestone for Aptar Pharma China,” stated Mrs Yan Jiang, Vice President Northeast Asia for Aptar Pharma.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance